Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT00431613
- Lead Sponsor
- Hellenic Oncology Research Group
- Brief Summary
The combination of chemotherapy with radiotherapy remains the standard of therapy for patients with stage III NSCLC. A recent phase II study has presented encouraging data regarding the administration of docetaxel as consolidation treatment after definitive concurrent chemo-radiotherapy.
- Detailed Description
To evaluate whether the administration of consolidation therapy with docetaxel/carboplatin after induction chemotherapy followed by concurrent chemoradiotherapy, offers any advantage regarding time to tumor progression
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 38
- histologically or cytologically confirmed, unresectable locally advanced (stage IIIA/IIIB) NSCLC
- no previous therapy for NSCLC is allowed
- age >18 years
- bidimensionally measurable disease
- performance status (WHO) 0-2
- absence of pleural effusion
- adequate liver (serum bilirubin < 1.5 times the upper normal limit (UNL); AST and ALT < 2.5 times the UNL in the absence of demonstrable liver metastases, or < 5 times the UNL in the presence of liver metastases); adequate renal function (serum creatinine < 1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function
- life expectancy of more than 3 months
- written informed consent
- active infection
- history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)
- malnutrition (loss of ≥ 20% of the original body weight)
- performance status: 3-4
- sensor or motor neuropathy > grade I
- second primary malignancy, except for non-melanoma skin cancer
- psychiatric illness or social situation that would preclude study compliance
- pregnant or lactating women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Gemcitabine DG -\> RT 2 Gemcitabine DG -\> RT -\> DCarbo 2 Carboplatin DG -\> RT -\> DCarbo 2 Chemoradiotherapy DG -\> RT -\> DCarbo 1 Docetaxel DG -\> RT 1 Chemoradiotherapy DG -\> RT 2 Docetaxel DG -\> RT -\> DCarbo
- Primary Outcome Measures
Name Time Method Time to tumor progression (TTP) 1 year
- Secondary Outcome Measures
Name Time Method Response rate Objective responses confirmed by CT or MRI (on 3rd and 6th cycle) Overall survival Probability of 1-year survival (%) Toxicity Toxicity assessment on each chemotherapy cycle Symptom improvement Assessment every two cycles Quality of life Assessment every two cycles
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (10)
University Hospital of Crete
🇬🇷Heraklion, Crete, Greece
University General Hospital of Alexandroupolis, Dep of Medical Oncology
🇬🇷Alexandroupolis, Greece
401 Military Hospital, Medical Oncology Unit
🇬🇷Athens, Greece
Air Forces Military Hospital, Dep of Medical Oncology
🇬🇷Athens, Greece
IASO General Hospital of Athens, 1st Dep of Medical Oncology
🇬🇷Athens, Greece
Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine
🇬🇷Athens, Greece
Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases
🇬🇷Athens, Greece
Sotiria General Hospital, 1st, 3rd, 6th, 7th, 8th Dep of Pulmonary Diseases
🇬🇷Athens, Greece
Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology
🇬🇷Piraeus, Greece
Theagenion Anticancer Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
University Hospital of Crete🇬🇷Heraklion, Crete, Greece